Adamis Pharmaceuticals Corporation (ADMP) Stock Moves Up After The Key clinical study
Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) jumped 3% after announcing patient dosing commencement in its Phase 2/3 clinical study for Tempol. Tempol is an oral antiviral treatment the company is developing to treat adult patients with COVID-19 infection. The antiviral product has demonstrated in preclinical studies that it has antioxidant, anti-inflammatory, and antiviral activity. Adamis is expected to recruit 248 patients in the study. Principal study investigator ShyamKottilil said that the timing…